SCHEMBL866899

SCHEMBL866899

CCCCCCCCCc1ccc(P(=O)(O)O)cc1.[Nd]

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.67
S1PR1 P21453 9/20 0.57
S1PR3 Q99500 9/20 0.57
S1PR2 O95136 7/20 0.57
S1PR4 O95977 5/20 0.57
ESR1 P03372 2/20 0.56
ADRA2A P08913 2/20 0.56
ADORA3 P0DMS8 2/20 0.56
TACR2 P21452 2/20 0.56
SLC6A2 P23975 2/20 0.56
SLC6A4 P31645 2/20 0.56
SLC6A3 Q01959 2/20 0.56
ALDH1A1 P00352 2/20 0.56
KDM4E B2RXH2 1/20 0.56
LMNA P02545 1/20 0.56
SHBG P04278 1/20 0.56
TP53 P04637 1/20 0.56
CYP3A4 P08684 1/20 0.56
HSPD1 P10809 1/20 0.56
ADRB3 P13945 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28629026 0.98 ENPP2 (0.69) ENPP2S1PR1S1PR3S1PR2S1PR4
SCHEMBL1100803 0.98 ENPP2 (0.69) ENPP2S1PR1S1PR3S1PR2S1PR4
SCHEMBL4237288 0.98 ENPP2 (0.69) ENPP2S1PR1S1PR3S1PR2S1PR4
SCHEMBL1100868 0.98 ENPP2 (0.69) ENPP2S1PR1S1PR3S1PR2S1PR4
SCHEMBL4263556 0.98 ENPP2 (0.69) ENPP2S1PR1S1PR3S1PR2S1PR4
SCHEMBL877356 0.98 ENPP2 (0.69) ENPP2S1PR1S1PR3S1PR2S1PR4
SCHEMBL4306211 0.98 ENPP2 (0.69) ENPP2S1PR1S1PR3S1PR2S1PR4
SCHEMBL12804620 0.96 ENPP2 (0.67) ENPP2S1PR1S1PR3S1PR2S1PR4
SCHEMBL2699482 0.96 ENPP2 (0.67) ENPP2S1PR1S1PR3S1PR2S1PR4
SCHEMBL7866712 0.96 ENPP2 (0.67) ENPP2S1PR1S1PR3S1PR2S1PR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371516-B2 Aged lanthanide-based catalyst systems and their use in the preparation of cis-1,4-polydienes BRIDGESTONE CORPORATION (JP) 2025-07-29 US disclosed
US-20230183399-A1 AGED LANTHANIDE-BASED CATALYST SYSTEMS AND THEIR USE IN THE PREPARATION OF CIS-1,4-POLYDIENES BRIDGESTONE CORPORATION (JP) 2023-06-15 US disclosed
US-9469706-B2 Polymers functionalized with unsaturated heterocycles containing a protected amino group BRIDGESTONE CORPORATION (JP) 2016-10-18 US disclosed
US-9458270-B2 Method for producing polydienes and polydiene copolymers with reduced cold flow BRIDGESTONE CORPORATION (JP) 2016-10-04 US disclosed
US-9447213-B2 Polymers functionalized with polycyano compounds BRIDGESTONE CORPORATION (JP) 2016-09-20 US disclosed
US-9376508-B2 Polymers and use thereof in preparation of high impact polymeric compositions BRIDGESTONE CORPORATION (JP) 2016-06-28 US disclosed
US-9353205-B2 Processes for the preparation of high-cis polydienes BRIDGESTONE CORPORATION (JP) 2016-05-31 US disclosed
US-9315599-B2 Functionalized polymers BRIDGESTONE CORPORATION (JP) 2016-04-19 US disclosed
US-20150299350-A1 Processes For The Preparation Of High-Cis Polydienes BRIDGESTONE CORPORATION (JP) 2015-10-22 US disclosed
US-20150267031-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORPORATION (JP) 2015-09-24 US disclosed
US-20110152449-A1 POLYMERS FUNCTIONALIZED WITH POLYOXIME COMPOUNDS AND METHODS FOR THEIR MANUFACTURE BRIDGESTONE CORPORATION (JP) 2011-06-23 US disclosed
US-20110144282-A1 POLYMERS FUNCTIONALIZED WITH IMIDE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP BRIDGESTONE CORPORATION (JP) 2011-06-16 US disclosed
US-7902309-B2 Process and catalyst system for polydiene production BRIDGESTONE CORPORATION (JP) 2011-03-08 US disclosed
US-20100317818-A1 POLYMERS FUNCTIONALIZED WITH HALOSILANES CONTAINING AN AMINO GROUP BRIDGESTONE CORPORATION (JP) 2010-12-16 US disclosed
US-20100216956-A1 PROCESS AND CATALYST SYSTEM FOR POLYDIENE PRODUCTION BRIDGESTONE CORPORATION (JP) 2010-08-26 US disclosed
US-7741418-B2 Process for producing polydienes BRIDGESTONE CORPORATION (JP) 2010-06-22 US disclosed
US-20100137520-A1 Branched Polymers and Methods for Their Synthesis and Use BRIDGESTONE CORPORATION (JP) 2010-06-03 US disclosed
US-20090171046-A1 PROCESS FOR PRODUCING POLYDIENES BRIDGESTONE CORPORATION (JP) 2009-07-02 US disclosed
US-20090171035-A1 POLYMERS FUNCTIONALIZED WITH POLYIMINE COMPOUNDS BRIDGESTONE CORPORATION (JP) 2009-07-02 US disclosed
US-20090099325-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORPORATION 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144282-A1 POLYMERS FUNCTIONALIZED WITH IMIDE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP PARG, PIN1, NPEPPS ENPP2 4673/4885S1PR1 4700/4885S1PR3 4550/4885
US-20100317818-A1 POLYMERS FUNCTIONALIZED WITH HALOSILANES CONTAINING AN AMINO GROUP MSN, PARG, ALG1 ENPP2 4440/4885S1PR1 3315/4885S1PR3 2601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.